TY - JOUR
T1 - A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis
T2 - results from the MSBase registry
AU - MSBase Study Group
AU - Spelman, Tim
AU - Ozakbas, Serkan
AU - Alroughani, Raed
AU - Terzi, Murat
AU - Hodgkinson, Suzanne
AU - Laureys, Guy
AU - Kalincik, Tomas
AU - Der Walt, Anneke Van
AU - Yamout, Bassem
AU - Lechner-Scott, Jeannette
AU - Soysal, Aysun
AU - Kuhle, Jens
AU - Sanchez-Menoyo, Jose Luis
AU - Morgado, Yolanda Blanco
AU - Spitaleri, Daniele LA
AU - Pesch, Vincent van
AU - Horakova, Dana
AU - Ampapa, Radek
AU - Patti, Francesco
AU - Macdonell, Richard
AU - Al-Asmi, Abdullah
AU - Gerlach, Oliver
AU - Oh, Jiwon
AU - Altintas, Ayse
AU - Tundia, Namita
AU - Wong, Schiffon L
AU - Butzkueven, Helmut
N1 - Publisher Copyright:
© 2023 The Authors.
PY - 2023/8/1
Y1 - 2023/8/1
N2 - WHAT IS THIS SUMMARY ABOUT?: Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad
®) compared with other oral treatments.
WHAT WERE THE RESULTS?: Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS.WHAT DO THE RESULTS MEAN?: The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.
AB - WHAT IS THIS SUMMARY ABOUT?: Patient registries contain anonymous data from people who share the same medical condition. The MSBase registry contains information from over 80,000 people living with multiple sclerosis (MS) across 41 countries. Using information from the MSBase registry, the GLIMPSE (Generating Learnings In MultiPle SclErosis) study looked at real-life outcomes in 3475 people living with MS who were treated with cladribine tablets (Mavenclad
®) compared with other oral treatments.
WHAT WERE THE RESULTS?: Results showed that people treated with cladribine tablets stayed on treatment for longer than other treatments given by mouth. They also had fewer relapses (also called flare ups of symptoms) than people who received a different oral treatment for their MS.WHAT DO THE RESULTS MEAN?: The results provide evidence that, compared with other oral treatments for MS, cladribine tablets are an effective medicine for people living with MS.
KW - cladribine tablets
KW - dimethyl fumarate (Tecfidera )
KW - fingolimod (Gilenya )
KW - lay summary
KW - multiple sclerosis
KW - relapses
KW - teriflunomide (Aubagio )
KW - treatment options
UR - http://www.scopus.com/inward/record.url?scp=85166398818&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85166398818&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/b9b78fb4-97f3-3ba9-9bee-5103d0b371fa/
U2 - 10.2217/nmt-2023-0005
DO - 10.2217/nmt-2023-0005
M3 - Review article
C2 - 37287269
SN - 1758-2024
VL - 13
SP - 215
EP - 221
JO - Neurodegenerative disease management
JF - Neurodegenerative disease management
IS - 4
ER -